Peter L. Gross

TL;DR: Extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of symptomatic venous thromboembolism after total hip or total knee arthroplasty.

TL;DR: The pharmacology of emerging anticoagulant agents, including idraparinux, a long-acting synthetic pentasaccharide that is given subcutaneously on a once-weekly basis, and new oral antICOagulants that target thrombin or factor Xa are reviewed.

TL;DR: Evidence is provided for the involvement of platelet PECAM-1 in the negative regulation of thrombus formation by using intravital microscopy and laser-induced injury to cremaster muscle arterioles to show that thrombi formed in PECam-1-deficient mice were larger, formed more rapidly than in control mice, and were more stable.

TL;DR: It is shown that tissue factor derived from hematopoietic cells is delivered by microparticles during the initial phase of thrombus development in vivo, and the accumulation of hematopolietic cell‐derived tissue factor in the developingThrombus correlates to the kinetics of microparticle accumulation and does not correlate temporally with leukocyte‐thrombus interaction.

TL;DR: PFn transfusion may be a potential therapy for bleeding disorders, particularly in association with anticoagulant therapy, and plays a self-limiting regulatory role in thrombosis by interacting with fibrin and platelet β3 integrin.